Last month, the German Federal Administrative Court issued a decision holding that, under certain circumstances, umbrella trademarks may be used for a portfolio of pharmaceutical products with different active ingredients where the products are labeled in the same indication and have a similar mode of action. However, whether physicians and consumers are misled by an umbrella, or common, trademark for products with different active ingredients must be decided on a case-by-case basis.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.